Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tunde Otulana Insider Profile
4 Followers
Tunde Otulana, Director at Allergy Therapeutics, holds 50.00K shares in Allergy Therapeutics (Ticker: GB:AGY). Most recently, Tunde Otulana Bought 25,000p shares of Allergy Therapeutics on Mar 16, 2018 for an estimated value of 9.70K.
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-47.70%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Tunde Otulana holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Mar 16, 2018 - Mar 16, 2019
Return:-47.10%
The most profitable trade made by Tunde Otulana
Tunde Otulana's Trading History
List of latest transactions for each holding click on a transaction to see Tunde Otulana's performance on stock
You May Also Like
Tunde Otulana insider profile FAQ
What is the percentage of profitable transactions made by Tunde Otulana?
The percentage of profitable transactions made by Tunde Otulana is 0%.
What is the average return per transaction made by Tunde Otulana?
The average return per transaction made by Tunde Otulana is -47.70%.
What stocks does Tunde Otulana hold?
Tunde Otulana holds: GB:AGY stocks.
What was Tunde Otulana’s latest transaction?
Tunde Otulana latest transaction was an Informative Buy of 9.70K.
What was Tunde Otulana's most profitable transaction?
Tunde Otulana’s most profitable transaction was an Informative Buy of GB:AGY stock on March 16, 2018. The return on the trade was -47.10%.
What is Tunde Otulana's role in Allergy Therapeutics?
Tunde Otulana's role in Allergy Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.